...moderate to severe RA who had an inadequate response to methotrexate showed that once-weekly subcutaneous BT-061... ...up to 7%. Patients received methotrexate plus placebo or once-weekly 25, 50 or 75 mg BT-061... ...in 2013. Biotest AG (Xetra:BIO), Dreieich, Germany AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Tregalizumab ( BT-061...
...response. Althaus said the most similar compound in development is AbbVie Inc. 's tregalizumab ( BT-061... ...a Phase II dose-finding study of tregalizumab in RA patients inadequately controlled on methotrexate , tregalizumab...
...through Phase II testing. Biotest did its first such deal last month by partnering its BT-061... ...the polyspecific immunoglobulin to treat antibody deficiency syndromes in 4Q11. The company's lead biotherapeutic is BT-061... ...psoriasis and preclinical studies for other immune-related diseases. Biotest granted Abbott exclusive, worldwide rights to BT-061...
